title: Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
abstract: Placebo controlled trials in over 25,000 women showed that tamoxifen reduced breast cancer risk by about 40% and osteoporotic fracture risk by about 32%. Similarly placebo controlled trials in nearly 18,000 women showed that raloxifene reduced breast cancer risk by 44-72% and osteoporotic fractures risk by 30-50%. A direct comparison of tamoxifen with raloxifene showed similar risk reduction for breast cancer and osteoporotic fractures with less toxicity for raloxifene.
authors.affiliation: Parkside Oncology Centre, Parkside, Wimbledon, London SW19 5NB, UK. hdummer@parkside-hospital.co.uk
authors.forename: Trevor J
authors.initials: TJ
authors.lastname: Powles
mesh_terms: D001943:Breast Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride